The highly anticipated Amylyx Pharmaceuticals recently disclosed significant progress in its research and development pipeline.

The company's highly anticipated Phase III clinical trial—Lucidity study—will have its key topline data revealed in the third quarter of 2026. The clarity of this timeline provides investors and the medical community with a clear expectation regarding the prospects of this drug. Based on this positive schedule, the company has further planned that if the trial results meet the expected targets, the commercialization process for the drug is expected to officially commence in 2027. This series of plans marks Amylyx's entry into a critical sprint phase in its exploration of the relevant therapeutic field.